https://doi.org/10.4081/gc.2021.9423

Serum interleukin-6 levels are higher in old age subjects with Alzheimer’s dementia

Vol. 7 No. 1 (2021)
Submitted: 23 October 2020
Accepted: 14 January 2021
Published: 19 February 2021
Aging, older, dementia, interleukin- 6, infection.
Abstract Views: 7216
PDF: 422
HTML: 147
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Virginia Boccardi
virginia.boccardi@unipg.it
Department of Medicine, Institute of Gerontology and Geriatrics, Santa Maria della Misericordia Hospital, University of Perugia, Italy.
Marta Baroni
Department of Medicine, Institute of Gerontology and Geriatrics, Santa Maria della Misericordia Hospital, University of Perugia, Italy.
Roberta Cecchetti
Department of Medicine, Institute of Gerontology and Geriatrics, Santa Maria della Misericordia Hospital, University of Perugia, Italy.
Michela Scamosci
Department of Medicine, Institute of Gerontology and Geriatrics, Santa Maria della Misericordia Hospital, University of Perugia, Italy.
Patrizia Bastiani
Department of Medicine, Institute of Gerontology and Geriatrics, Santa Maria della Misericordia Hospital, University of Perugia, Italy.
Patrizia Mecocci
Department of Medicine, Institute of Gerontology and Geriatrics, Santa Maria della Misericordia Hospital, University of Perugia, Italy.

Elevated interleukin-6 (IL-6) levels have been found positively associated with markers of physical frailty as well as identified as a potential biomarker of Alzheimer’s disease (AD). Thus, we explored the levels of plasma IL-6 at baseline in a cohort of older subjects with or without cognitive impairment, which results may have also implications for coronavirus disease 2019 (COVID-19) clinical management. This is a retrospective study including a cohort of over 60 years old-age subjects, 72 healthy controls, 95 mild cognitive impairment, and 73 AD were included in the study. Plasma IL-6 was measured in all subjects. The sample population included 240 subjects, mostly women with a mean age of 78.61±6.30 (range: 60-93) years. Age significantly correlated with IL-6 plasma levels (r=0.204, P=0.002) even after controlling by gender. No difference was found in body mass index (BMI), nutritional status (assessed by mini nutritional assessment), and comorbidity indices (cumulative illness rating scaleseverity and comorbidity index) among groups. Instead, IL-6 significantly differed, having patients affected by AD higher levels compared to the other groups. Final linear regression analysis showed that independently of age, gender, BMI, nutritional status, number of clinically relevant concomitant diseases, the diagnosis of AD was associated with higher IL-6 plasma levels. These data indicate that serum IL-6 is more elevated in AD, supporting that IL-6 may have also a potential role in response to COVID-19 in old age subjects with cognitive impairment.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol Ser A Biol Sci Med Sci 2002;57:M326. DOI: https://doi.org/10.1093/gerona/57.5.M326
Puzianowska-Kuźnicka M, Owczarz M, Wieczorowska-Tobis K, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Ageing 2016;13:21. DOI: https://doi.org/10.1186/s12979-016-0076-x
Daynes RA, Araneo BA, Ershler WB, et al. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993;150:5219-30.
Satizabal CL, Zhu YC, Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012;78:720-7. DOI: https://doi.org/10.1212/WNL.0b013e318248e50f
Wu Y-Y, Hsu J-L, Wang H-C, et al. Alterations of the neuroinflammatory markers IL-6 and TRAIL in Alzheimer’s disease. Dement Geriatr Cogn Dis Extra 2015;5:424-34. DOI: https://doi.org/10.1159/000439214
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020 [Epub ahead of print]. DOI: https://doi.org/10.1093/cid/ciaa248
Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv 2020 [Epub ahead of print]. DOI: https://doi.org/10.1101/2020.02.29.20029520
Zhou F, Yu T, Du R, et al. Articles clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet 2020;6736:1-9.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 2011;7:270-9. DOI: https://doi.org/10.1016/j.jalz.2011.03.008
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94. DOI: https://doi.org/10.1111/j.1365-2796.2004.01388.x
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 2011;7:263-9. DOI: https://doi.org/10.1016/j.jalz.2011.03.005
Folstein MF, Folstein SE, McHugh PR. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98. DOI: https://doi.org/10.1016/0022-3956(75)90026-6
Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72. DOI: https://doi.org/10.1192/bjp.140.6.566
Boccardi V, Conestabile Della Staffa M, Baroni M, et al. Prevalence and correlates of behavioral disorders in old age subjects with cognitive impairment: results from the ReGAl project. J Alzheimers Dis 2017;60:1275-83.
Mariani E, Monastero R, Ercolani S, et al. Influence of comorbidity and cognitive status on instrumental activities of daily living in amnestic mild cognitive impairment: results from the ReGAl project. Int J Geriatr Psychiatry 2008;23:523-30. DOI: https://doi.org/10.1002/gps.1932
Yesavage JA, Sheikh JI. 9/Geriatric Depression Scale (GDS). Clin Gerontol 1986;5:165-73. DOI: https://doi.org/10.1300/J018v05n01_09
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86. DOI: https://doi.org/10.1093/geront/9.3_Part_1.179
Vellas B, Guigoz Y, Garry PJ, et al. The mini nutritional assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999;15:116-22. DOI: https://doi.org/10.1016/S0899-9007(98)00171-3
Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-48. DOI: https://doi.org/10.1016/0165-1781(92)90005-N
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;0. DOI: https://doi.org/10.1016/S0140-6736(20)30628-0
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 [Epub ahead of print]. DOI: https://doi.org/10.1007/s00134-020-06028-z
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014;69:S4-9. DOI: https://doi.org/10.1093/gerona/glu057
Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012;8:1254-66. DOI: https://doi.org/10.7150/ijbs.4679
Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer’s disease: A systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry 2017;88:876-82. DOI: https://doi.org/10.1136/jnnp-2017-316201
Hwang JM, Kim JH, Park JS, et al. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci 2020 [Epub ahead of print]. DOI: https://doi.org/10.1007/s10072-020-04541-z
Miyashita S, Yamada T, Mikami T, et al. Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 ( COVID ‐19): an experience in New York. Geriatr Gerontol Int 2020;20:732-4. DOI: https://doi.org/10.1111/ggi.13942

How to Cite

Boccardi, V., Baroni, M., Cecchetti, R., Scamosci, M., Bastiani, P., & Mecocci, P. (2021). Serum interleukin-6 levels are higher in old age subjects with Alzheimer’s dementia. Geriatric Care, 7(1). https://doi.org/10.4081/gc.2021.9423

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.